| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/25/2006 | US20060111348 synergistic mixture of [1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazol-4-yl]-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)-methanone and hypotensive agent; insulin resistance, dyslipidemia, obesity |
| 05/25/2006 | US20060111323 Use of polysiloxanes having quaternary ammonium groups as formulation auxiliaries, and compositions comprising them |
| 05/25/2006 | US20060111290 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 05/25/2006 | US20060111284 Method for treating cancer |
| 05/25/2006 | US20060110743 Drug evolution: drug design at hot spots |
| 05/25/2006 | US20060110465 Compositions addressing inflammation and/or degenerative disorders |
| 05/25/2006 | US20060110460 dissolving active principle in water; emulsifying resulting solution of active principle with d,l-lactide-co-glycolide matrix copolymer, emulsifying first emulsion in external aqueous phase containing surfactant, viscosity-enhancing agent, osmotic agent, extraction-evaporation to form microspheres |
| 05/25/2006 | US20060110452 Dosage forms of risedronate |
| 05/25/2006 | US20060110444 Gemfibrozil, fenofibrate, bezafibrate, clofibrate, ciprofibrate and active metabolites and analogues dissolved in a vehicle, which is hydrophobic, hydrophilic or water-miscible; improved bioavailability of the active ingredient upon oral administration |
| 05/25/2006 | US20060110443 toxic or potent core is incorporated into the dosage form via three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder; allows greater bioavailability |
| 05/25/2006 | US20060110409 Targeted agents for nerve regeneration |
| 05/25/2006 | US20060110372 Regulatory cells that control T cell immunoreactivity |
| 05/25/2006 | US20060110367 Compositions and methods for inhibiting pathogenic growth |
| 05/25/2006 | US20060110363 Comprises chimeric polypeptide associated with uracil phosphoribosyl transferase (UPRTase) treating proliferative and infectious diseases; gene therapy; antiproliferative agents; suicide genes |
| 05/25/2006 | US20060110332 Agent for medicamentous treatment of acute and chronic pain |
| 05/25/2006 | US20060110324 Human anti-epidermal growth factor receptor single-chain antibodies |
| 05/24/2006 | EP1659172A1 Adipogenic differentiation of human mesenchymal stem cells |
| 05/24/2006 | EP1659131A2 Polypeptides and nucleic acids encoding the same |
| 05/24/2006 | EP1659125A1 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 05/24/2006 | EP1658879A1 Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| 05/24/2006 | EP1658860A1 Drug compositions comprising anticholinergics and EGFR kinase inhibitors |
| 05/24/2006 | EP1658858A2 Use of botulinum toxin for the treatment of unstable bladder |
| 05/24/2006 | EP1658856A1 Exendins for glucagon suppression |
| 05/24/2006 | EP1658851A1 Anti-asthmatic combinations comprising surface active phospholipids |
| 05/24/2006 | EP1658849A2 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 05/24/2006 | EP1658098A1 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1658097A1 Nucleotide and cellular vaccine composition |
| 05/24/2006 | EP1658096A1 Method of inducing immune tolerance |
| 05/24/2006 | EP1658093A2 Use of a mixture containing neuropeptides and steroids for treating disturbances of psychosocial experiences and behaviour |
| 05/24/2006 | EP1658092A1 A method for treating cancer patients undergoing chemotherapy |
| 05/24/2006 | EP1658089A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| 05/24/2006 | EP1658087A1 Blood sugar regulating agent comprising a natural dry product derived from from soya bean seeds alone or in a mixture and preparation thereof |
| 05/24/2006 | EP1658083A1 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids |
| 05/24/2006 | EP1658082A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1658081A2 Immunosuppressive effects of pteridine derivatives |
| 05/24/2006 | EP1658079A1 Multivitamin syrup for children or young adults |
| 05/24/2006 | EP1658078A2 Methods for intradermal delivery of therapeutics agents |
| 05/24/2006 | EP1658075A2 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis |
| 05/24/2006 | EP1658060A2 Methods of treating copd and pulmonary hypertension |
| 05/24/2006 | EP1658059A1 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 05/24/2006 | EP1658058A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1553942B1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 05/24/2006 | EP1453431A4 Method and apparatus for the stimulation of hair growth |
| 05/24/2006 | EP1334106B1 Imidazole derivatives, production method thereof and use thereof |
| 05/24/2006 | EP1212410B1 Dna encoding the human serine protease eos |
| 05/24/2006 | EP1115397B1 Compositions for mitigating the adverse effects of interleukin-2 |
| 05/24/2006 | EP1039887B1 Use of aminothiol compounds for the treatment of neuro- and nephro-disorders and therapeutic toxicities |
| 05/24/2006 | EP1015585B1 Tie ligand homologues |
| 05/24/2006 | EP0973563B1 System for dialysis and shock treatment |
| 05/24/2006 | EP0946147B1 Composition suitable for the treatment of equine laminitis |
| 05/24/2006 | EP0858337B1 A pharmaceutical composition for the treatment of autoimmune diseases |
| 05/24/2006 | EP0719295B1 Polymeric matrices and their uses in pharmaceutical compositions |
| 05/24/2006 | DE10248601B4 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/24/2006 | DE102004056579A1 Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid Inhaled anticholinergic drugs containing a new, salmeterol, and a steroid |
| 05/24/2006 | DE102004056578A1 Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid Inhaled medicines containing a new anticholinergic, formoterol and a steroid |
| 05/24/2006 | CN1777676A Schizophrenia-related voltage-gated ion channel gene and protein |
| 05/24/2006 | CN1777670A New strains of bifidobacterium having the ability to produce glutamine |
| 05/24/2006 | CN1777596A Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders |
| 05/24/2006 | CN1777445A Agent for repairing corneal perception |
| 05/24/2006 | CN1777434A Agent for preventing and ameliorating constipation |
| 05/24/2006 | CN1777415A Medicinal composition containing edible acid or its acid salt and its use |
| 05/24/2006 | CN1777363A Ss-l-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
| 05/24/2006 | CN1775801A Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 05/24/2006 | CN1775289A Multi vitamin oral disintegrating tablet formulation and its preparing method |
| 05/24/2006 | CN1775288A Medicine for treating diarrhoea |
| 05/24/2006 | CN1775214A Rifapentine, refampicin, rifabutin or rifamdin injection and its preparing method |
| 05/24/2006 | CN1775211A Method and composition for reducing to xicity related to leflunomide treatment |
| 05/24/2006 | CN1257286C Targeted adenovirus vectors for delivery of heterologous genes |
| 05/24/2006 | CN1256941C Body fat level controllers |
| 05/23/2006 | US7049422 Tumor necrosis related receptor, TR7 |
| 05/23/2006 | US7049412 Genetic engineered nucleic acids codes these enzymes; therapy for bone disorders; monoclonal antibodies |
| 05/23/2006 | US7049403 Insulin/IGF/relaxin family polypeptides and DNAS thereof |
| 05/23/2006 | US7049402 Tumor necrosis factor receptor-5 |
| 05/23/2006 | US7049340 administering ramipril, ramiprilat or other ramiprilat derivative; for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies involving vascular factor, in particular glaucomatous neuropathy, degenerative choriopathy of strong myopia |
| 05/23/2006 | US7049339 comprises zinc sulphate, copper sulphate, an organic acid, an alkali metal salt; more effective at applying an active ingredient to a hoof than a conventional, non-colloid system; treatment of digital dermatitis |
| 05/23/2006 | US7049336 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 05/23/2006 | US7049332 Effective against mutations; such as 2,3-Dihydro-4-ethyl-1-(3-methylphenylamino)-5-phenyl-1H-imidazole-2-thione |
| 05/23/2006 | US7049326 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
| 05/23/2006 | US7049321 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor |
| 05/23/2006 | US7049320 Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis |
| 05/23/2006 | US7049319 Colon cleansing composition and method |
| 05/23/2006 | US7049302 A saponin possessing immune adjuvant activity, derived from Quillaja saponaria; an immunostimulatory oligonucleotide cotaining an unmethylated CpG dinucleotide,wherein the immunostimulatory oligonucleotide is not a part of a DNA vaccine vector |
| 05/23/2006 | US7049295 Compounds and use thereof to modify transport across cell membranes |
| 05/23/2006 | US7049124 Hyaluronidase from the Hirudinaria manillensis isolation, purification and recombinant method of production |
| 05/23/2006 | US7049119 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2006 | US7049117 Comprises chimeric polypeptide associated with uracil phosphoribosyl transferase (UPRTase) treating proliferative and infectious diseases; gene therapy; antiproliferative agents; suicide genes |
| 05/23/2006 | US7049084 Neuroblastoma cell lines expressing the α2δ subunit of calcium channels and methods therefore |
| 05/23/2006 | US7049066 Diagnosis and treatment of myocardial failure |
| 05/23/2006 | US7048950 Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations |
| 05/23/2006 | US7048928 Inhibitor of histamine synthesis, especially of of histidine decarboxylase such as tritoqualine; allergen, e.g., cysteine protease |
| 05/23/2006 | US7048927 treating a cardiovascular disease, especially preventing restenosis in a blood vessel which may occur following a cardiovascular procedure, |
| 05/23/2006 | US7048924 Combination antiviral and interleukin-2 therapy for HIV infection |
| 05/23/2006 | US7048914 Placental alkaline phosphatase to control diabetes |
| 05/23/2006 | US7048909 Aerosols containing nondegraded atenolol, pindolol, esmolol, propranolol, or metoprolol |
| 05/23/2006 | US7048906 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 05/23/2006 | CA2339630C Carboline derivatives as cgmp phosphodiesterase inhibitors |
| 05/23/2006 | CA2245206C Use of an inhibitor of excitatory amino acids in a cosmetic or dermatological compound for sensitive skin, and the compound thus obtained |
| 05/18/2006 | WO2006053162A1 Ptpase inhibitors and t-cell activators for treating cancer |
| 05/18/2006 | WO2006053160A2 Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| 05/18/2006 | WO2006052569A1 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |